STENTYS Revenues For The First 9 Months Of 2012 Up 88% Over Prior Year

STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world's first and only Self-Apposing ® stent to treat acute myocardial infarction (AMI), today reports its third-quarter and 9-month revenues through 30 September 2012.
  • Quarterly and 9-month revenues
  9 months Quarterly – 3 months
€ thousands

9 months 2012

9 months 2011
    Var % Q3 2012     Q3 2011     Var %
Revenues 1,823.2     970.0     +88.0% 673.6     371.0     +81.6%

Revenues for the third quarter of 2012 and for the first 9 months of the year totaled €673.6 thousand and €1,823.2 thousand, respectively. These figures represent 88% growth over the first 9 months of 2011. The revenue results reflect momentum from the growing adoption of STENTYS stents by cardiologists in the 8 European countries where premarketing activities are underway.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, concludes: “ Our third-quarter sales performance is in line with our market plan and our robust growth is suggestive of the potential we believe our Self-Apposing stent platform represents, particularly in clinical settings such as AMI.”

Upcoming Financial Results

STENTYS expects to publish its 2012 annual revenues on 29 January 2013, after market.


STENTYS is developing and commercializing innovative solutions for the treatment of patients with acute myocardial infarction (AMI, or heart attack) and complex coronary artery disease. STENTYS Self-Apposing ® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters, particularly in the post-infarction phase, in order to prevent the malapposition problems associated with conventional stents. In the APPOSITION III clinical trial, STENTYS stents demonstrated a very low 30-day mortality rate among 1,000 high-risk AMI patients when compared to recent studies with conventional stents. More information is available at .

This press release contains forward looking statements about the Company’s business and prospects. Such forward looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, including with respect to a pre-market approval for the Company’s BMS, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2011 Registration Document (document de référence) filed with the Autorité des marchés financiers (the “AMF”) in France on June 25, 2012 under number R.12-033 as such section may be updated from time to time.

STENTYS is listed on Compartment C of the NYSE Euronext ParisISIN: FR0010949404 – Ticker: STNT

Copyright Business Wire 2010